SILO
Silo Pharma, Inc.
$6.63
+2.95%
$107.8M
No data for this timeframe.
Vol
Market Cap$107.8M
Cap SizeMicro Cap
Reddit Sentiment80° Bullish
SEC Reports4
Press Releases2
Recent Activity
Jun 3, 2026
SEC
Silo Pharma filed a Certificate of Change effecting a 1-for-15 reverse stock split, effective June 2, 2026, to regain co
8-K — Impact 4/10
Jun 1, 2026
SEC
Silo Pharma announced a 1-for-15 reverse stock split effective June 2, 2026, reducing shares outstanding from ~16.27M to
8-K — Impact 2/10
Jun 1, 2026
short_volume
Short Volume: SILO — 55.3% short (0.5M / 0.9M)
Short: 485,171 | Exempt: 178,058 | TRF Vol: 877,260 | Short Ratio: 55.3% | Off-exchange volume (dark
Apr 29, 2026
Press
Silo Pharma issued a press release highlighting recent U.S. federal actions supporting psychedelic therapeutics, includi
Impact 2/10
Apr 22, 2026
Press
Silo Pharma announced the launch of a new AI subsidiary following its acquisition of Qwikagents.ai assets, marking a str
Impact 6/10
Apr 16, 2026
SEC
Silo Pharma's registration statement for the resale of up to 3,071,428 shares of common stock, issuable upon exercise of
EFFECT — Impact 6/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 28, 2023 | Laidlaw & Co. | INITIATE | Buy |
Latest Reports
NEUTRAL
8-K
4/10
Silo Pharma filed a Certificate of Change effecting a 1-for-15 reverse stock split, effective June 2, 2026, to regain co
Jun 3, 2026
NEUTRAL
8-K
2/10
Silo Pharma announced a 1-for-15 reverse stock split effective June 2, 2026, reducing shares outstanding from ~16.27M to
Jun 1, 2026
NEUTRAL
Press
2/10
Silo Pharma issued a press release highlighting recent U.S. federal actions supporting psychedelic therapeutics, includi
Apr 29, 2026
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
4/10
Silo Pharma filed a Certificate of Change effecting a 1-for-15 reverse stock split, effective June 2
Jun 3, 2026
NEUTRAL
8-K
2/10
Silo Pharma announced a 1-for-15 reverse stock split effective June 2, 2026, reducing shares outstan
Jun 1, 2026
BEARISH
EFFECT
6/10
Silo Pharma's registration statement for the resale of up to 3,071,428 shares of common stock, issua
Apr 16, 2026
NEUTRAL
EFFECT
4/10
Silo Pharma's S-1 registration for the resale of up to 3,071,428 shares of common stock underlying p
Apr 14, 2026
Historical analyst distribution (last covering-analyst action Aug 2023): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 28, 2023 | Laidlaw & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Dec 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Undervalued Penny Setups I’m Watching Closely
▲ 1
💬 1
⚡ 0.5
Jun 1, 2026
short_volume
Short Volume: SILO — 55.3% short (0.5M / 0.9M)
Short: 485,171 | Exempt: 178,058 | TRF Vol: 877,260 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 7, 2026
other
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
<p><b><i>New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines</i>
May 7, 2026
earnings_calendar
SILO Q1 2026 Earnings Scheduled — 2026-05-07
Apr 29, 2026
announcement
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
<p><i>Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment</i><
Apr 23, 2026
short_volume
Short Volume: SILO — 55.4% short (1.0M / 1.8M)
Short: 1,011,134 | Exempt: 150,972 | TRF Vol: 1,824,521 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
m_and_a
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
<p><i>Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1</i></p>
Apr 20, 2026
other
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
<p><i>SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies</i></p>
Apr 20, 2026
short_volume
Short Volume: SILO — 56.5% short (4.9M / 8.7M)
Short: 4,910,452 | Exempt: 13,763 | TRF Vol: 8,696,999 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: SILO — 66.2% short (0.9M / 1.3M)
Short: 864,796 | Exempt: 8,309 | TRF Vol: 1,306,862 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: SILO — 55.0% short (1.4M / 2.5M)
Short: 1,389,877 | Exempt: 24,498 | TRF Vol: 2,526,477 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: SILO — 58.6% short (0.3M / 0.5M)
Short: 320,455 | Exempt: 11,959 | TRF Vol: 547,001 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: SILO — 57.2% short (18.6M / 32.5M)
Short: 18,575,604 | Exempt: 122,143 | TRF Vol: 32,497,630 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
other
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
<p align="center"><i>EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio</i></p>
Mar 26, 2026
earnings_calendar
SILO Q4 2025 Earnings After Market Close — 2026-03-26